CDSCO allows Serum Institute to enrol 7-11 year-olds in COVID vaccine trial
Bengaluru: India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect children from the coronavirus.
It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.
"After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol," a subject expert panel of the Central Drugs Standard Control Organization said.
Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of U.S. drugmaker Novavax's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.
Read also: Serum Institute, Novavax apply to WHO for emergency use listing of Covid-19 vaccine
So far, only drugmaker Zydus Cadila's DNA COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.
Read also: Serum Institute to invest Rs 501 crore in Oxford Biomedica
